Skip to main content
Log in

Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

A series of quinoxaline analogs of the herbicide Assure® was found to have selective cytotoxicity for solid tumors of mice in a disk-diffusion-soft-agar-colony-formation-assay compared to L1210 leukemia. Four agents without selective cytotoxicity and 14 agents with selective cytotoxicity were evaluated in vivo for activity against a solid tumor. The four agents without selective cytotoxicity in the disk-assay were inactive in vivo (T/C > 42%). Thirteen of the fourteen agents with selectivity in the disk-assay were active in vivo (T/C < 42%). Five of the agents had curative activity. These five agents had a halogen (F, Cl, Br) in the 7-position (whereas Assure® had a Cl in the 6 position). All agents with curative activity were either a carboxylic acid, or a derivative thereof, whereas Assure® is the ethyl ester of the carboxylic acid. All other structural features were identical between Assure® and the curative agents. Assure® had no selective cytotoxicity for solid tumors in the disk-assay, and was devoid of antitumor activity. The analog XK469 is in clinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Branda RF, McCormack JJ, Perlmutter CA: Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound inmurine B16 melanoma cells. Biochem Pharmacol 37: 4557–4564, 1988

    Google Scholar 

  2. Branda RF, Moore AL, McCormack JJ: Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol 38: 3521–3526, 1989

    Google Scholar 

  3. Rigas JR, Francis PA, Miller VA et al.: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 35(6): 483– 488, 1995

    Google Scholar 

  4. Conley BA, O'Hara S, Wu S et al.: Phase I trial of chloroquinoxaline sulfonamide with correlation of its pharmacoki netics and pharmacodynamics. Cancer Chemother Pharmacol 37: 139–149, 1995

    Google Scholar 

  5. Miller VA, Rigas JR, Tong WP et al.: Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 40(4): 415–418, 1997

    Google Scholar 

  6. Craciunescu et al.: An R Acad Farm 51: 653–658, 1985

    Google Scholar 

  7. Foster et al.: Invest New Drugs 3: 401–410, 1985

    Google Scholar 

  8. Katagiri K, Yoshida T, Sato K: Quinoxaline antibiotics. In: Antibiotics, Vol III, Mechanism of Action of Antimicrobial and Antitumor Agents. Corcorn and Hahn (eds), Springer-Verlag, pp 234–251, 1974

  9. Piatti SE, Bekerman D, Gaozza CH: Es </del>Sintesis de Derivados de bis-quinoxalina con posible actividad antineoplasica. Anales de Quimica, Ser. C 82: 85–89, 1986

    Google Scholar 

  10. Piatti SE, Nuber N, Krotz L, Gaozza CH: Sintesis de Derivados de Bisaminoquinoxalina. Ensayos de Interaccion con adn y de citotoxicidad. Anales de Quimica 85: 105–109, 1989

    Google Scholar 

  11. Zegar I, Graslund A, Bergman J, Eriksson M, Norden B: Interaction of ellipticine and a Indolo [2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides. Chem Biol Interactions 72: 277–293, 1989

    Google Scholar 

  12. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.

  13. LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical antitumor activity of XK469. EORTC 104,1994

  14. LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical Antitumor Activity of XK469. Proc. of AACR 35: 401, 1994

    Google Scholar 

  15. Corbett T, Valeriote F, LoRusso P et al.: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Intern J Pharmacognosy (Supp) 33: 102–122, 1995

    Google Scholar 

  16. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42: 1707–1715, 1982

    Google Scholar 

  17. Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold Jr DP, Schabel Jr FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187– 1200, 1982

    Google Scholar 

  18. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5: 3–20, 1987

    Google Scholar 

  19. Corbett TH, Valeriote FA: Rodent Models in Experimental Chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, R.F. Kallman (ed) Pergamon Press, Chapt. 50, pp 233–247, 1987

  20. Corbett TH, Valeriote FA, Polin L et al.: Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. FA Valeriote, TH Corbett, LH Baker (eds), Kluwer Academic Publishers, pp 33–87, Boston/Dordrecht/London, 1992

  21. Corbett T, Valeriote F, LoRusso P et al.: In Vivo Methods for Screening and Preclinical Testing; Use of rodent solid tumors for drug discovery. In: The Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. B Teicher (ed), Humana Press Inc., Totowa, NJ Chapt-5, pp 75–99, 1997

    Google Scholar 

  22. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434–2439, 1975

    Google Scholar 

  23. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660–2680, 1977

    Google Scholar 

  24. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57Bl/6 mice. Cancer Res 44: 717–726, 1984

    Google Scholar 

  25. Corbett TH: A selective two-tumor soft agar assay for drug discovery. AACR, Abst. No. 1289, 25: 325, 1984

    Google Scholar 

  26. Corbett T, Valeriote F, Baker L et al.: Antitumor activity of N-[[1–[[2–(Diethylamino)ethyl]amino]-9–oxo-9H-Thioxanthen-4–y1]methyl]metanesulfonamide (WIN33377) and analogs: Expert Opinion on Investigational Drugs 3(12): 1281–1292, 1994

    Google Scholar 

  27. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of cryptophycin-8. J Exper Therap Oncol 1: 95–108, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corbett, T.H., LoRusso, P., Demchick, L. et al. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 16, 129–139 (1998). https://doi.org/10.1023/A:1006174622061

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006174622061

Navigation